Analysts See $-1.18 EPS for Ascendis Pharma A/S (ASND); W.W. Grainger (GWW) SI Decreased By 13.47%

W.W. Grainger, Inc. (NYSE:GWW) Logo

Analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to report $-1.18 EPS on March, 27.They anticipate $0.10 EPS change or 9.26% from last quarter’s $-1.08 EPS. After having $-0.94 EPS previously, Ascendis Pharma A/S’s analysts see 25.53% EPS growth. The stock increased 0.30% or $0.36 during the last trading session, reaching $120.61. About 247,050 shares traded. Ascendis Pharma A/S (NASDAQ:ASND) has risen 89.47% since March 11, 2018 and is uptrending. It has outperformed by 85.10% the S&P500. Some Historical ASND News: 29/03/2018 – ASCENDIS PHARMA A/S ASND.O : LEERINK RAISES TARGET PRICE TO $64 FROM $37; 07/05/2018 – Ascendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology; 02/04/2018 – Ascendis Pharma A/S Appoints Thomas A. Larson as Chief Commercial Officer; 30/05/2018 – ASCENDIS PHARMA A/S – CONTINUED EXECUTION AND ACHIEVEMENT OF PLANNED MILESTONES ACROSS 3 WHOLLY-OWNED CLINICAL PROGRAMS IN RARE ENDOCRINE DISEASES; 28/03/2018 – ASCENDIS PHARMA A/S – RARE DISEASE ENDOCRINOLOGY PIPELINE ADVANCES, WITH SIGNIFICANT MILESTONES ANTICIPATED OVER NEXT TWELVE MONTHS; 24/04/2018 – JETBLUE: PLANS TO INCREASE TRANSCON FLIGHTS FROM L.A. BASIN; 19/03/2018 Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at ENDO 2018; 02/04/2018 – Fidelity Select Pharmaceuticals Adds Ascendis Pharma A/S; 28/03/2018 – Ascendis Pharma A/S Reports Full Year 2017 Financial Results; 25/04/2018 – Ascendis Pharma A/S Announces Upcoming Investor Presentations

W.W. Grainger Inc (NYSE:GWW) had a decrease of 13.47% in short interest. GWW’s SI was 3.19M shares in March as released by FINRA. Its down 13.47% from 3.68M shares previously. With 376,100 avg volume, 9 days are for W.W. Grainger Inc (NYSE:GWW)’s short sellers to cover GWW’s short positions. The SI to W.W. Grainger Inc’s float is 7.03%. The stock decreased 1.44% or $4.3 during the last trading session, reaching $293.4. About 356,998 shares traded. W.W. Grainger, Inc. (NYSE:GWW) has risen 18.34% since March 11, 2018 and is uptrending. It has outperformed by 13.97% the S&P500. Some Historical GWW News: 19/04/2018 – WW Grainger Raises 2018 View To EPS $14.30-EPS $15.30; 23/04/2018 – W W GRAINGER INC GWW.N : UBS RAISES TARGET PRICE TO $240 FROM $220; 19/04/2018 – WW Grainger 1Q EPS $4.07; 19/04/2018 – WW Grainger 1Q Net $231.5M; 15/05/2018 – JANA PARTNERS LLC – CHANGE IN HOLDINGS ARE AS OF MARCH 31, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF DEC 31, 2017; 25/04/2018 – Grainger Increases Quarterly Dividend By 6.3 Percent; 09/04/2018 – W W GRAINGER INC GWW.N : BMO RAISES TARGET PRICE TO $247 FROM $242; 19/04/2018 – WW Grainger Raises Year Sales Guidance to Range of 5% to 8%; 25/04/2018 – Grainger’s Shareholders Elect 11 Directors And Other Meeting Highlights; 21/04/2018 – DJ WW Grainger Inc, Inst Holders, 1Q 2018 (GWW)

Among 5 analysts covering Ascendis Pharma (NASDAQ:ASND), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ascendis Pharma had 6 analyst reports since January 24, 2019 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, March 7 by J.P. Morgan. The rating was maintained by Cantor Fitzgerald on Monday, March 4 with “Buy”. The company was maintained on Monday, March 4 by Canaccord Genuity. As per Thursday, March 7, the company rating was maintained by Wedbush. The firm earned “Outperform” rating on Thursday, January 24 by Leerink Swann.

More notable recent Ascendis Pharma A/S (NASDAQ:ASND) news were published by: Seekingalpha.com which released: “Ascendis Pharma prices equity offering at $120 – Seeking Alpha” on March 06, 2019, also Seekingalpha.com with their article: “Ascendis Pharma: Positioned To Target Growth Hormone Deficiency In Children – Seeking Alpha” published on February 26, 2019, Nasdaq.com published: “Mid-Morning Market Update: Markets Open Higher; Childrens Place Misses Q4 Expectations – Nasdaq” on March 04, 2019. More interesting news about Ascendis Pharma A/S (NASDAQ:ASND) were released by: Nasdaq.com and their article: “Mid-Day Market Update: U.S. Stocks Turn Negative; Dow Down Over 350 Points – Nasdaq” published on March 04, 2019 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 03/04/2019: ASND,CSII,NTRI,TVTY,NITE,INO – Nasdaq” with publication date: March 04, 2019.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $5.58 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

W.W. Grainger, Inc. distributes maintenance, repair, and operating supplies; and other related services and products that are used by businesses and institutions in the United States, Canada, Europe, Asia, and Latin America. The company has market cap of $16.34 billion. It operates through two divisions, U.S. and Canada. It has a 21.37 P/E ratio. The firm offers material handling equipment, safety and security supplies, lighting and electrical products, power and hand tools, pumps and plumbing supplies, cleaning and maintenance supplies, building and home inspection supplies, vehicle and fleet components, and various other products.

Investors sentiment decreased to 0.74 in Q4 2018. Its down 0.07, from 0.81 in 2018Q3. It worsened, as 73 investors sold W.W. Grainger, Inc. shares while 189 reduced holdings. 55 funds opened positions while 139 raised stakes. 46.01 million shares or 10.63% more from 41.59 million shares in 2018Q3 were reported. Morgan Stanley holds 0.02% or 228,491 shares in its portfolio. Essex Svcs has 885 shares for 0.08% of their portfolio. Prudential Fin has 55,755 shares for 0.03% of their portfolio. 16,376 are held by Kayne Anderson Rudnick Investment Mgmt Ltd Llc. Aqr Cap Ltd Company owns 299,587 shares. Bessemer Gp Incorporated has 186 shares for 0% of their portfolio. Indiana-based Indiana Mgmt has invested 0.13% in W.W. Grainger, Inc. (NYSE:GWW). Golub Group Lc invested in 1.61% or 58,331 shares. Hall Laurie J Trustee holds 0.18% or 1,040 shares in its portfolio. Moreover, Montecito Bancorp Tru has 0.18% invested in W.W. Grainger, Inc. (NYSE:GWW) for 1,800 shares. 1,090 were reported by Fairfield Bush & Co. Savant Cap Ltd Limited Liability Company has invested 0.05% in W.W. Grainger, Inc. (NYSE:GWW). Mu invested in 19,000 shares or 3.95% of the stock. Jensen Inv Mngmt Inc reported 2,280 shares. Catalyst Cap Advsr Ltd Liability Corp holds 0.59% or 56,000 shares in its portfolio.

W.W. Grainger, Inc. (NYSE:GWW) Institutional Positions Chart

"

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.